Swallowing outcomes following Intensity Modulated Radiation Therapy (IMRT) for head & neck cancer - A systematic review
ABSTRACT A systematic review to establish what evidence is available for swallowing outcomes following IMRT for head and neck cancer.
Online electronic databases were searched to identify papers published in English from January 1998 to December 2009. Papers were independently appraised by two reviewers for methodological quality, method of swallowing evaluation and categorized according to the World Health Organisation's International Classification of Health Functions. The impact of radiation dose to dysphagia aspiration risk structures (DARS) was also evaluated.
Sixteen papers met the inclusion criteria. The literature suggests that limiting the radiation dose to certain structures may result in favourable swallowing outcomes. Methodological limitations included variable assessment methods and outcome measures and heterogeneity of patients. There are only limited prospective data, especially where pre-treatment measures have been taken and compared to serial post-treatment assessment.
Few studies have investigated the impact of IMRT on swallow function and the impact on everyday life. Initial studies have reported potential benefits but are limited in terms of study design and outcome data. Further well designed, prospective, longitudinal swallowing studies including multidimensional evaluation methods are required to enable a more comprehensive understanding of dysphagia complications and inform pre-treatment counselling and rehabilitation planning.
- SourceAvailable from: Judith E Raber-Durlacher
[Show abstract] [Hide abstract]
- "Thus, studies aimed at identification of the dysphagia/aspiration-related structures (DARSs) (Eisbruch et al., 2004) (e.g., the pharyngeal constrictors, tongue base, and larynx), altered-mastication-related structures or (AMRSs) (Teguh et al., 2008; Johnson et al., 2010; Van der Molen et al., 2011, 2013) (e.g., the masseter and pterygoid muscles, the temporo-mandibular joints, and the oral cavity), and xerostomia-related structures or XRSs (Van de Water et al., 2009; Jellema et al., 2005) (e.g., the major and minor salivary glands) have been undertaken in recent years. As a consequence, RT techniques sparing the above-mentioned structures have been employed and they seem to improve patients' health-related quality of life (HRQoL) (Pow et al., 2006; Nutting et al., 2011; Bhide et al., 2009), even when RT is combined with CT (Hancock et al., 2003; Roe et al., 2010; Van der Laan et al., 2012). Yet, few studies report the exact dose-volume correlation for each individual DARS, AMRS and XRS (Nutting et al., 2011; Caudell et al., 2010; Eisbruch et al., 2011; Jensen et al., 2007; Levendag et al., 2007; Li et al., 2009; Bhide et al., 2012), and the majority of these are retrospective. "
ABSTRACT: Radiotherapy alone or in combination with chemotherapy and/or surgery is the typical treatment for head and neck cancer patients. Acute side effects (such as oral mucositis, dermatitis, salivary changes, taste alterations, etc.), and late toxicities in particular (such as osteo-radionecrosis, hypo-salivation and xerostomia, trismus, radiation caries etc.), are often debilitating. These effects tend to be underestimated and insufficiently addressed in the medical community. A multidisciplinary group of head and neck cancer specialists met in Milan with the aim of reaching a consensus on clinical definitions and management of these toxicities. The Delphi Appropriateness method was used for developing the consensus, and external experts evaluated the conclusions. This paper contains 10 clusters of statements about the clinical definitions and management of head and neck cancer treatment sequels (dental pathologies and osteo-radionecroses) that reached consensus, and offers a review of the literature about these topics. The review was split into two parts: the first part dealt with dental pathologies and osteo-radionecroses (10 clusters of statements), whereas this second part deals with trismus and xerostomia. Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.Critical reviews in oncology/hematology 08/2015; DOI:10.1016/j.critrevonc.2015.08.010 · 4.03 Impact Factor
Perspectives on Swallowing and Swallowing Disorders (Dysphagia) 06/2015; 24:79-88. DOI:10.1044/sasd24.3.79
- "The inconsistency between objective swallowing outcomes and patient-reported outcomes observed in these studies demonstrates that measuring the impact of dysphagia through instrumental assessments in this population alone does not provide a holistic picture of functioning. It has become increasingly apparent that to fully explore and understand the complexity of dysphagia post HNC, clinicians need to take a multidimensional assessment approach incorporating multiple outcome measures designed to provide greater insight into the impact of dysphagia on people with HNC (Frowen & Perry, 2006; Roe et al., 2010). This holistic approach is consistent with the International Classification of Functioning, Disability and Health (ICF), which emphasises the importance of viewing health conditions using a biopsychosocial perspective (World Health Organization, 2001). "
[Show abstract] [Hide abstract]
- "During the last decade, radiation oncology has witnessed an explosion in innovation of treatment modalities: intensity modulated radiotherapy (IMRT) allows to deliver a high radiation dose to the tumor, with improved target conformality and surrounding healthy tissue sparing, in comparison with three-dimensional (3D) plans [5-7]. "
ABSTRACT: To report our initial clinical experience of helical tomotherapy (HT) in the treatment of locally advanced oropharynx and inoperable oral cavity cancer. Between February 2008 and January 2011, 24 consecutive patients, 15 with oropharyngeal cancer and 9 with oral cavity cancer were treated with exclusive radiotherapy or concomitant chemoradiotherapy. Simultaneous integrated boost (SIB) in 30 fractions scheme was prescribed to all patients, using Helical Tomotherapy. Doses administered to primary tumor, oropharynx/oral cavity and positive lymph-nodes and negative lymph-nodes were 66--67.5 Gy, 60--63 Gy and 54 Gy, respectively. Complete response rate for the oropharynx and the oral cavity group was 86.7% and 77.8%, respectively. The 1 and 2-year Overall Survival (OS) and Disease Free Survival (DFS) rate for the oropharynx group was 92.9%, 85.1%, 92.9% and 77.4% respectively. For the oral cavity group, 1 and 2-year OS and DFS rates were 55.6%, 55.6%, 75% and 75%, respectively. No patient developed grade >=3 mucositis, dysphagia or dermatitis. The maximum late-toxicity grade observed was 2, for all the variables examined. HT appears to achieve encouraging clinical outcomes in terms of response, survival and toxicity rates.Radiation Oncology 09/2013; 8(1):210. DOI:10.1186/1748-717X-8-210 · 2.55 Impact Factor